NO178187C - Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-aminopiperidin-derivater og beslektede nitrogenholdige heterocykliske forbindelser - Google Patents

Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-aminopiperidin-derivater og beslektede nitrogenholdige heterocykliske forbindelser

Info

Publication number: NO178187C
Authority: NO; Norway
Prior art keywords: preparation; therapeutically active; containing heterocyclic; heterocyclic compounds; analogous process
Prior art date: 1990-01-04

Application number

NO910016A

Other languages

English (en)

Other versions

NO910016L (no

NO910016D0 (no

NO178187B (no

Inventor

Manoj C Desai

Terry J Rosen

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-01-04

Filing date

1991-01-03

Publication date

1996-02-07

1991-01-03 Application filed by Pfizer filed Critical Pfizer

1991-01-03 Publication of NO910016D0 publication Critical patent/NO910016D0/no

1991-07-05 Publication of NO910016L publication Critical patent/NO910016L/no

1995-10-30 Publication of NO178187B publication Critical patent/NO178187B/no

1996-02-07 Publication of NO178187C publication Critical patent/NO178187C/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Immunology (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Rheumatology (AREA)
Addiction (AREA)
Dermatology (AREA)
Hydrogenated Pyridines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

NO910016A 1990-01-04 1991-01-03 Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-aminopiperidin-derivater og beslektede nitrogenholdige heterocykliske forbindelser NO178187C (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US1990/000116 WO1991009844A1 (en)	1990-01-04	1990-01-04	Substance p antagonists

Publications (4)

Publication Number	Publication Date
NO910016D0 NO910016D0 (no)	1991-01-03
NO910016L NO910016L (no)	1991-07-05
NO178187B NO178187B (no)	1995-10-30
NO178187C true NO178187C (no)	1996-02-07

Family

ID=22220614

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO910016A NO178187C (no)	1990-01-04	1991-01-03	Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-aminopiperidin-derivater og beslektede nitrogenholdige heterocykliske forbindelser

Country Status (27)

Country	Link
EP (2)	EP0436334B1 (no)
JP (1)	JPH0757748B2 (no)
KR (1)	KR930009441B1 (no)
CN (2)	CN1035944C (no)
AT (1)	ATE115127T1 (no)
AU (1)	AU625511B2 (no)
BR (1)	BR9100016A (no)
CA (1)	CA2033497C (no)
CZ (1)	CZ289485B6 (no)
DE (1)	DE69014848T2 (no)
DK (1)	DK0436334T3 (no)
ES (1)	ES2064667T3 (no)
FI (2)	FI114096B (no)
GR (1)	GR3014940T3 (no)
HU (5)	HUT68179A (no)
IE (1)	IE63770B1 (no)
IL (3)	IL112348A (no)
MY (1)	MY105438A (no)
NO (1)	NO178187C (no)
NZ (1)	NZ236581A (no)
PL (5)	PL164244B1 (no)
PT (1)	PT96405B (no)
RU (1)	RU2105758C1 (no)
UA (1)	UA41251C2 (no)
WO (1)	WO1991009844A1 (no)
YU (1)	YU48026B (no)
ZA (1)	ZA9136B (no)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6218364B1 (en)	1988-06-20	2001-04-17	Scott L. Harbeson	Fluorinated neurokinin A antagonists
US5830863A (en) *	1988-06-20	1998-11-03	Merrell Pharmaceuticals Inc.	Neurokinin A antagonists
US5232929A (en) *	1990-11-28	1993-08-03	Pfizer Inc.	3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5332817A (en) *	1990-01-04	1994-07-26	Pfizer Inc.	3-aminopiperidine derivatives and related nitrogen containing heterocycles
US5364943A (en) *	1991-11-27	1994-11-15	Pfizer Inc.	Preparation of substituted piperidines
PL168236B1 (pl) *	1990-05-31	1996-01-31	Pfizer	Sposób wytwarzania podstawionych piperydyn PL PL PL
AU648317B2 (en) *	1990-06-01	1994-04-21	Pfizer Inc.	3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
CA2086434C (en) *	1990-07-23	1998-09-22	John A. Lowe, Iii	Quinuclidine derivatives
SK284185B6 (sk) *	1991-03-26	2004-10-05	Pfizer Inc.	Spôsob prípravy substituovaných piperidínov
US5716965A (en) *	1991-05-22	1998-02-10	Pfizer Inc.	Substituted 3-aminoquinuclidines
UA39168C2 (uk) *	1991-06-20	2001-06-15	Пфайзер, Інк.	Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі
TW202432B (no) *	1991-06-21	1993-03-21	Pfizer
EP0600952B1 (en) *	1991-08-20	1996-04-17	MERCK SHARP & DOHME LTD.	Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
ATE195867T1 (de) *	1991-09-20	2000-09-15	Glaxo Group Ltd	Neue medizinische indikation für tachykinin- antagonisten
GB9201179D0 (en) *	1992-01-21	1992-03-11	Glaxo Group Ltd	Chemical compounds
FR2688219B1 (fr)	1992-03-03	1994-07-08	Sanofi Elf	Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
US5444074A (en) *	1992-04-15	1995-08-22	Merck Sharp & Dohme Limited	Piperidine tachykinin receptor antagonists
EP0636130A1 (en) *	1992-04-15	1995-02-01	Merck Sharp & Dohme Ltd.	Azacyclic compounds
ES2164657T3 (es) *	1992-05-18	2002-03-01	Pfizer	Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
US5719147A (en) *	1992-06-29	1998-02-17	Merck & Co., Inc.	Morpholine and thiomorpholine tachykinin receptor antagonists
US6048859A (en)	1992-06-29	2000-04-11	Merck & Co., Inc.	Morpholine and thiomorpholine tachykinin receptor antagonists
CA2099233A1 (en) *	1992-06-29	1993-12-30	Conrad P. Dorn	Morpholine and thiomorpholine tachykinin receptor antagonists
US5637699A (en) *	1992-06-29	1997-06-10	Merck & Co., Inc.	Process for preparing morpholine tachykinin receptor antagonists
EP0652866B1 (en) *	1992-07-28	1998-11-25	MERCK SHARP & DOHME LTD.	Azacyclic compounds
AU4396193A (en) *	1992-08-04	1994-03-03	Pfizer Inc.	3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
GB9216911D0 (en) *	1992-08-10	1992-09-23	Merck Sharp & Dohme	Therapeutic agents
US5387595A (en) *	1992-08-26	1995-02-07	Merck & Co., Inc.	Alicyclic compounds as tachykinin receptor antagonists
AU4973693A (en) *	1992-09-10	1994-03-29	Merck Sharp & Dohme Limited	Alcohols and ethers with aromatic substituents as tachykinin-antagonists
GB9220286D0 (en) *	1992-09-25	1992-11-11	Merck Sharp & Dohme	Therapeutic agents
US5344830A (en) *	1992-12-10	1994-09-06	Merck & Co., Inc.	N,N-diacylpiperazine tachykinin antagonists
DK0675886T3 (da) *	1992-12-10	2000-09-18	Pfizer	Aminomethylensubstituerede ikke-aromatiske heterocykler og deres anvendelse som substance P-antagonister
US6369074B1 (en) *	1992-12-10	2002-04-09	Pfizer Inc.	Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
US5830854A (en) *	1992-12-14	1998-11-03	Merck Sharp & Dohme, Limited	Method of treating cystic fibrosis using a tachykinin receptor antagonist
GB9300051D0 (en) *	1993-01-04	1993-03-03	Merck Sharp & Dohme	Therapeutic agents
JPH08506823A (ja) *	1993-02-18	1996-07-23	メルクシヤープエンドドームリミテツド	アザ環式化合物、該化合物を含む組成物及びタキキニン拮抗剤としての該化合物の使用
US5496833A (en) *	1993-04-13	1996-03-05	Merck Sharp & Dohme Limited	Piperidine tachykinin receptor antagonists
WO1994027966A1 (en) *	1993-05-28	1994-12-08	Pfizer Inc.	Process for preparing and resolving 2-phenyl-3-aminopiperidine
US5348955A (en) *	1993-06-22	1994-09-20	Merck & Co., Inc.	N,N-diacylpiperazines
GB9317104D0 (en) *	1993-08-17	1993-09-29	Zeneca Ltd	Therapeutic heterocycles
US6083943A (en) *	1993-09-17	2000-07-04	Pfizer Inc	Substituted azaheterocyclecarboxylic acid
WO1995007886A1 (en) *	1993-09-17	1995-03-23	Pfizer Inc.	3-amino-5-carboxy-substituted piperidines and 3-amino-4-carboxy-substituted pyrrolidines as tachykinin antagonists
EP1209157A1 (en) *	1993-09-17	2002-05-29	Pfizer Inc.	Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds
IL111002A (en) *	1993-09-22	1998-09-24	Glaxo Group Ltd	Piperidine derivatives their preparation and pharmaceutical compositions containing them
TW263498B (no) *	1993-11-10	1995-11-21	Takeda Pharm Industry Co Ltd
US5728716A (en) *	1994-01-28	1998-03-17	Merck Sharp & Dohme Limited	Aralkylamino substituted azacyclic therapeutic agents
US5610165A (en) *	1994-02-17	1997-03-11	Merck & Co., Inc.	N-acylpiperidine tachykinin antagonists
TW385308B (en) *	1994-03-04	2000-03-21	Merck & Co Inc	Prodrugs of morpholine tachykinin receptor antagonists
GB9408872D0 (en) *	1994-05-03	1994-06-22	Zeneca Ltd	Heterocyclic compounds
GB9418545D0 (en) *	1994-09-15	1994-11-02	Merck Sharp & Dohme	Therapeutic agents
FR2725900B1 (fr) *	1994-10-21	1997-07-18	Sanofi Sa	Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
US5998444A (en) *	1995-10-24	1999-12-07	Zeneca Ltd.	Piperidinyl compounds as NK1 or NK2 antagonists
EP0709375B1 (en) *	1994-10-25	2005-05-18	AstraZeneca AB	Therapeutic heterocycles
US6008223A (en) *	1994-10-27	1999-12-28	Zeneca Limited	Therapeutic compounds
FR2728166A1 (fr)	1994-12-19	1996-06-21	Oreal	Composition topique contenant un antagoniste de substance p
FR2728165A1 (fr)	1994-12-19	1996-06-21	Oreal	Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr)	1994-12-19	1996-06-21	Oreal	Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2729952B1 (fr) *	1995-01-30	1997-04-18	Sanofi Sa	Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729954B1 (fr) *	1995-01-30	1997-08-01	Sanofi Sa	Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2741262B1 (fr)	1995-11-20	1999-03-05	Oreal	Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
DK0780375T3 (da)	1995-12-21	2002-10-07	Pfizer	3-((5-substitueret benzyl)amino)-2-phenylpiperidiner som substans P-antagonister
WO1998014193A1 (en) *	1996-10-04	1998-04-09	Alcon Laboratories, Inc.	The use of a substance p antagonist for the manufacture of a medicament for the treatment of ocular pain
US5750549A (en) *	1996-10-15	1998-05-12	Merck & Co., Inc.	Cycloalkyl tachykinin receptor antagonists
JP2001524960A (ja) *	1997-04-24	2001-12-04	メルクシヤープエンドドームリミテツド	摂食障害を治療するためのｎｋ−１受容体拮抗薬の使用
CA2298779A1 (en) *	1997-08-04	1999-02-18	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
AU738047B2 (en) *	1997-08-04	2001-09-06	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating mania
GB9716457D0 (en) *	1997-08-04	1997-10-08	Merck Sharp & Dohme	Therapeutic agents
GB9716463D0 (en) *	1997-08-04	1997-10-08	Merck Sharp & Dohme	Therapeutic agents
GB9816897D0 (en) *	1998-08-04	1998-09-30	Merck Sharp & Dohme	Therapeutic use
ES2198948T3 (es) *	1998-08-25	2004-02-01	Novartis Ag	Usos de antagonistas de la substancia p para el tratamiento del sindrome de la fatiga cronica y/o de la fibromialgia.
DK1246806T3 (da)	1999-11-03	2008-06-16	Amr Technology Inc	Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
US7163949B1 (en)	1999-11-03	2007-01-16	Amr Technology, Inc.	4-phenyl substituted tetrahydroisoquinolines and use thereof
CN1416346A (zh)	2000-03-21	2003-05-07	史密丝克莱恩比彻姆公司	蛋白酶抑制剂
WO2002004455A2 (en)	2000-07-11	2002-01-17	Albany Molecular Research, Inc	4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
AU2001292320A1 (en) *	2000-10-02	2002-04-15	Tanabe Seiyaku Co., Ltd.	Benzylamine compound, process for producing the same, and intermediate therefor
US6709651B2 (en)	2001-07-03	2004-03-23	B.M.R.A. Corporation B.V.	Treatment of substance P-related disorders
WO2003057668A1 (en) *	2001-12-28	2003-07-17	Takeda Chemical Industries, Ltd.	Nitrogenous cyclic ketone derivative, process for producing the same, and use
US7220098B2 (en)	2003-05-27	2007-05-22	General Electric Company	Wear resistant variable stator vane assemblies
KR101389246B1 (ko)	2004-07-15	2014-04-24	브리스톨-마이어스스퀴브컴파니	아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
CA2584422A1 (en)	2004-10-18	2006-04-27	Eli Lilly And Company	1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists
GB0423356D0 (en) *	2004-10-21	2004-11-24	Merck Sharp & Dohme	Therapeutic agents
US7543992B2 (en)	2005-04-28	2009-06-09	General Electric Company	High temperature rod end bearings
US8362075B2 (en)	2005-05-17	2013-01-29	Merck Sharp & Dohme Corp.	Cyclohexyl sulphones for treatment of cancer
NZ565111A (en)	2005-07-15	2011-10-28	Amr Technology Inc	Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
JP5489333B2 (ja)	2006-09-22	2014-05-14	メルク・シャープ・アンド・ドーム・コーポレーション	脂肪酸合成阻害剤を用いた治療の方法
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CA2674436C (en)	2007-01-10	2012-07-17	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
AU2008208920A1 (en)	2007-01-24	2008-07-31	Glaxo Group Limited	Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or R(-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an NK1
AU2008233662B2 (en)	2007-04-02	2012-08-23	Msd K.K.	Indoledione derivative
EP2170076B1 (en)	2007-06-27	2016-05-18	Merck Sharp & Dohme Corp.	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AU2009222122A1 (en)	2008-03-03	2009-09-11	Tiger Pharmatech	Tyrosine kinase inhibitors
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es)	2008-06-04	2010-07-28	Bristol Myers Squibb Co	Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
UA105182C2 (ru)	2008-07-03	2014-04-25	Ньюрексон, Інк.	Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010086251A1 (en) *	2009-01-27	2010-08-05	F. Hoffmann-La Roche Ag	Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors
US8691825B2 (en)	2009-04-01	2014-04-08	Merck Sharp & Dohme Corp.	Inhibitors of AKT activity
ES2446971T3 (es)	2009-05-12	2014-03-11	Albany Molecular Research, Inc.	Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
AU2010247763B2 (en)	2009-05-12	2015-12-24	Albany Molecular Research, Inc.	7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
ES2528404T3 (es)	2009-05-12	2015-02-10	Bristol-Myers Squibb Company	Formas cristalinas de (S)-7-([1,2,4]triazol[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y sus usos
US8859776B2 (en)	2009-10-14	2014-10-14	Merck Sharp & Dohme Corp.	Substituted piperidines that increase p53 activity and the uses thereof
WO2011163330A1 (en)	2010-06-24	2011-12-29	Merck Sharp & Dohme Corp.	Novel heterocyclic compounds as erk inhibitors
CA2805265A1 (en)	2010-08-02	2012-02-09	Merck Sharp & Dohme Corp.	Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
HRP20191232T1 (hr)	2010-08-17	2019-11-01	Sirna Therapeutics Inc	Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina)
EP2608669B1 (en)	2010-08-23	2016-06-22	Merck Sharp & Dohme Corp.	NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en)	2010-09-01	2015-02-03	Merck Sharp & Dohme Corp.	Indazole derivatives useful as ERK inhibitors
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
DK2632472T3 (en)	2010-10-29	2018-03-19	Sirna Therapeutics Inc	RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2654748B1 (en)	2010-12-21	2016-07-27	Merck Sharp & Dohme Corp.	Indazole derivatives useful as erk inhibitors
AU2012245455A1 (en)	2011-04-21	2013-10-31	Merck Sharp & Dohme Corp.	Insulin-Like Growth Factor-1 Receptor inhibitors
EP2770987B1 (en)	2011-10-27	2018-04-04	Merck Sharp & Dohme Corp.	Novel compounds that are erk inhibitors
EP2844261B1 (en)	2012-05-02	2018-10-17	Sirna Therapeutics, Inc.	SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
JP6280554B2 (ja)	2012-09-28	2018-02-14	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	Ｅｒｋ阻害剤である新規化合物
HK1215170A1 (zh)	2012-11-14	2016-08-19	The Johns Hopkins University	治療精神分裂症的方法和組合物
AU2013352568B2 (en)	2012-11-28	2019-09-19	Merck Sharp & Dohme Llc	Compositions and methods for treating cancer
KR102196882B1 (ko)	2012-12-20	2020-12-30	머크 샤프 앤드 돔 코포레이션	Hdm2 억제제로서의 치환된 이미다조피리딘
US9540377B2 (en)	2013-01-30	2017-01-10	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en)	2013-09-03	2016-07-07	Moderna Therapeutics, Inc.	Circular polynucleotides
US10975084B2 (en)	2016-10-12	2021-04-13	Merck Sharp & Dohme Corp.	KDM5 inhibitors
WO2019094312A1 (en)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
WO2019094311A1 (en)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
CN111918647A (zh) *	2018-02-26	2020-11-10	圣拉斐尔医院有限公司	用于治疗眼痛的nk-1拮抗剂
EP3833667B1 (en)	2018-08-07	2024-03-13	Merck Sharp & Dohme LLC	Prmt5 inhibitors
CN112805006B (zh)	2018-08-07	2024-09-24	默沙东有限责任公司	Prmt5抑制剂
EP3833668B1 (en)	2018-08-07	2025-03-19	Merck Sharp & Dohme LLC	Prmt5 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL89969C (no) *	1954-02-05
GB1060160A (en) *	1964-08-05	1967-03-01	Allen & Hanburys Ltd	4-phenylpiperidine derivatives
US3560510A (en) *	1969-03-05	1971-02-02	Aldrich Chem Co Inc	2-benzhydrylquinuclidines
US3992389A (en) *	1970-09-03	1976-11-16	John Wyeth & Brother Limited	Heterocyclic compounds
MX18467A (es) *	1988-11-23	1993-07-01	Pfizer	Agentes terapeuticos de quinuclidinas
PL168236B1 (pl) *	1990-05-31	1996-01-31	Pfizer	Sposób wytwarzania podstawionych piperydyn PL PL PL

1990
- 1990-01-04 WO PCT/US1990/000116 patent/WO1991009844A1/en not_active Ceased
- 1990-01-04 UA UA5010406A patent/UA41251C2/uk unknown
- 1990-12-14 DE DE69014848T patent/DE69014848T2/de not_active Expired - Fee Related
- 1990-12-14 EP EP90313680A patent/EP0436334B1/en not_active Expired - Lifetime
- 1990-12-14 AT AT90313680T patent/ATE115127T1/de not_active IP Right Cessation
- 1990-12-14 EP EP19930201034 patent/EP0558156A3/en not_active Ceased
- 1990-12-14 ES ES90313680T patent/ES2064667T3/es not_active Expired - Lifetime
- 1990-12-14 DK DK90313680.2T patent/DK0436334T3/da active
- 1990-12-20 NZ NZ236581A patent/NZ236581A/xx unknown
- 1990-12-28 JP JP2409476A patent/JPH0757748B2/ja not_active Expired - Fee Related
- 1990-12-28 IL IL112348A patent/IL112348A/en not_active IP Right Cessation
- 1990-12-28 IL IL96821A patent/IL96821A/xx not_active IP Right Cessation
1991
- 1991-01-02 MY MYPI91000002A patent/MY105438A/en unknown
- 1991-01-02 PL PL91293389A patent/PL164244B1/pl unknown
- 1991-01-02 HU HU9203405A patent/HUT68179A/hu unknown
- 1991-01-02 HU HU9203404A patent/HU220602B1/hu unknown
- 1991-01-02 PL PL91293392A patent/PL164205B1/pl not_active IP Right Cessation
- 1991-01-02 PL PL91293391A patent/PL164204B1/pl not_active IP Right Cessation
- 1991-01-02 PT PT96405A patent/PT96405B/pt active IP Right Grant
- 1991-01-02 HU HU9203403A patent/HUT68130A/hu unknown
- 1991-01-02 CA CA002033497A patent/CA2033497C/en not_active Expired - Fee Related
- 1991-01-02 PL PL91293390A patent/PL164203B1/pl not_active IP Right Cessation
- 1991-01-02 AU AU68621/91A patent/AU625511B2/en not_active Ceased
- 1991-01-02 PL PL91288592A patent/PL163967B1/pl not_active IP Right Cessation
- 1991-01-02 HU HU916A patent/HUT60719A/hu unknown
- 1991-01-02 HU HU9203403A patent/HU222724B1/hu not_active IP Right Cessation
- 1991-01-03 IE IE791A patent/IE63770B1/en not_active IP Right Cessation
- 1991-01-03 BR BR919100016A patent/BR9100016A/pt not_active Application Discontinuation
- 1991-01-03 NO NO910016A patent/NO178187C/no unknown
- 1991-01-03 KR KR1019910000001A patent/KR930009441B1/ko not_active Expired - Fee Related
- 1991-01-03 YU YU491A patent/YU48026B/sh unknown
- 1991-01-03 ZA ZA9136A patent/ZA9136B/xx unknown
- 1991-01-03 CN CN91100039A patent/CN1035944C/zh not_active Expired - Fee Related
- 1991-01-03 FI FI910034A patent/FI114096B/fi active
- 1991-01-04 CZ CS199110A patent/CZ289485B6/cs not_active IP Right Cessation
- 1991-12-23 RU SU5010406A patent/RU2105758C1/ru not_active IP Right Cessation
1993
- 1993-08-20 CN CN93116286A patent/CN1045595C/zh not_active Expired - Fee Related
1995
- 1995-01-16 IL IL11234895A patent/IL112348A0/xx unknown
- 1995-02-01 GR GR950400206T patent/GR3014940T3/el unknown
2004
- 2004-04-01 FI FI20040479A patent/FI20040479A7/fi not_active Application Discontinuation

Also Published As

Publication number	Publication date
NZ236581A (en)	1992-10-28
IL112348A (en)	1998-06-15
KR930009441B1 (ko)	1993-10-04
CN1087083A (zh)	1994-05-25
IL96821A0 (en)	1991-09-16
IL112348A0 (en)	1995-03-30
FI20040479A7 (fi)	2004-04-01
PL293392A1 (en)	1992-07-13
HUT68180A (en)	1995-05-29
PL164204B1 (pl)	1994-06-30
FI910034L (fi)	1991-07-05
RU2105758C1 (ru)	1998-02-27
EP0436334A3 (en)	1992-05-27
PL164203B1 (pl)	1994-06-30
BR9100016A (pt)	1991-10-22
HUT68130A (en)	1995-05-29
PL293390A1 (en)	1992-07-13
NO910016L (no)	1991-07-05
YU48026B (sh)	1996-10-09
EP0558156A2 (en)	1993-09-01
DE69014848D1 (de)	1995-01-19
EP0436334A2 (en)	1991-07-10
JPH04103570A (ja)	1992-04-06
ZA9136B (en)	1992-08-26
CN1045595C (zh)	1999-10-13
PT96405A (pt)	1991-10-15
PL293389A1 (en)	1992-07-13
PL288592A1 (en)	1992-06-15
NO910016D0 (no)	1991-01-03
PL293391A1 (en)	1992-07-13
IE63770B1 (en)	1995-06-14
DE69014848T2 (de)	1995-05-04
HU222724B1 (hu)	2003-09-29
IL96821A (en)	1997-03-18
EP0436334B1 (en)	1994-12-07
ATE115127T1 (de)	1994-12-15
HUT68179A (en)	1995-05-29
PL163967B1 (pl)	1994-06-30
MY105438A (en)	1994-10-31
CN1053060A (zh)	1991-07-17
AU625511B2 (en)	1992-07-16
DK0436334T3 (da)	1995-02-13
AU6862191A (en)	1991-07-18
HUT60719A (en)	1992-10-28
UA41251C2 (uk)	2001-09-17
JPH0757748B2 (ja)	1995-06-21
CA2033497A1 (en)	1991-07-05
FI114096B (fi)	2004-08-13
FI910034A0 (fi)	1991-01-03
CA2033497C (en)	1997-01-07
WO1991009844A1 (en)	1991-07-11
HU910006D0 (en)	1991-08-28
EP0558156A3 (en)	1993-10-06
ES2064667T3 (es)	1995-02-01
PT96405B (pt)	1998-06-30
KR910014350A (ko)	1991-08-31
CN1035944C (zh)	1997-09-24
HU220602B1 (hu)	2002-03-28
CZ289485B6 (cs)	2002-02-13
YU491A (sh)	1994-01-20
CS1091A3 (en)	1991-08-13
PL164244B1 (en)	1994-07-29
IE910007A1 (en)	1991-07-17
NO178187B (no)	1995-10-30
PL164205B1 (en)	1994-06-30
GR3014940T3 (en)	1995-05-31

Publication	Publication Date	Title
NO178187C (no)	1996-02-07	Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-aminopiperidin-derivater og beslektede nitrogenholdige heterocykliske forbindelser
NO934470L (no)	1988-08-22	Analogifremgangsmaate for fremstilling av terapeutisk aktive, mett ede, heterocykliske carboxamidderivater
NO177387C (no)	1995-09-06	Analogifremgangsmåte for fremstilling av terapeutisk aktive imidazo-kondenserte, 6-leddede, heterocykliske forbindelser
FI905941A0 (fi)	1990-12-03	Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten 2-asyyliaminotiatsolijohdannaisten valmistamiseksi
FI892787L (fi)	1989-12-11	Analogiamenetelmä terapeuttisesti käyttökelpoisten 1-indolyylialkyyli-4-(substituoitu pyridinyyli)piperatsiinien valmistamiseksi
NO179283C (no)	1996-09-11	Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte azoler
NO178068C (no)	1996-01-17	Analogifremgangsmåte for fremstilling av terapeutisk aktive tiazolidindionderivater
FI894604L (fi)	1990-03-29	Menetelmä uusien terapeuttisesti käyttökelpoisten pyridyyli- ja pyrimidyylipiperatsiinijohdannaisten valmistamiseksi
NO175976C (no)	1995-01-11	Analogifremgangsmåte for fremstilling av terapeutisk aktive 4-(1,6-dihydro-6-okso-pyridazinyl-3-oksy)-3-kromanolderivater
PH25106A (en)	1991-02-19	1-acyl-3-(4-(2-pyrimidinyl)-1-piperazinyl) propanes, pharmaceutical composition containing said compound and method of use thereof
FI906084L (fi)	1991-06-12	Menetelmä uusien terapeuttisesti käyttökelpoisten 5-(2-metyyli-4,4,4-trifluoributyylikarbamoyyli)indolijohdannaisten valmistamiseksi
HU913967D0 (en)	1992-02-28	Pesticide preparations containinb 2-aryl-5-(trifluor-methyl)-pyrrhol derivatives and process for the production of the active agents
HUT46507A (en)	1988-11-28	Insecticidal composition comprising 5-member heterocyclic derivatives of n'-substituted-n,n'-diacylhydrazine compounds and process for producing such compounds
GB2247237B (en)	1994-05-18	1-(N'-Cyanoguanyl) derivatives of N-containing five-membered ring heterocycles
FI880282L (fi)	1988-07-28	Menetelmä uusien terapeuttisesti käyttökelpoisten 3-aryyli-5-alkyylisulfinyyli- ja sulfonyyli-4H-1,2,4-triatsolien valmistamiseksi
FI894812A0 (fi)	1989-10-11	Menetelmä valmistaa farmakologisesti arvokkaita 2-karbonyylisubstituoituja N,N'-di(trimetoksibentsoyyli)piperatsiineja
FI915518A7 (fi)	1992-05-25	Menetelmä lääkinnällisesti vaikuttavien heterosyklisesti substituoitujen piperatsinoalkyylibentsoksatsiini- ja -tiatsiiniyhdisteiden valmistamiseksi
FI97388B (fi)	1996-08-30	Menetelmä heterosyklisten NMDA-antagonistien valmistamiseksi
NO954076L (no)	1992-06-09	Fremgangsmåte for fremstilling av en krystallform og et farmasöytisk preparat derav
NO174419C (no)	1994-05-04	Analogifremgangsmåte for fremstilling av terapeutisk aktive heterocykliske forbindelser